BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9781645)

  • 1. Medullary thyroid carcinoma: search for histological predictors of survival (109 proband cases analysis).
    Franc B; Rosenberg-Bourgin M; Caillou B; Dutrieux-Berger N; Floquet J; Houcke-Lecomte M; Justrabo E; Lange F; Labat-Moleur F; Le Bodic MF; Patey M; Beauchet A; Saint-André JP; Hejblum G; Viennet G
    Hum Pathol; 1998 Oct; 29(10):1078-84. PubMed ID: 9781645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine.
    Modigliani E; Cohen R; Campos JM; Conte-Devolx B; Maes B; Boneu A; Schlumberger M; Bigorgne JC; Dumontier P; Leclerc L; Corcuff B; Guilhem I
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):265-73. PubMed ID: 9578814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Causes of death in patients with medullary cancer of the thyroid. GETC. Groupe d'Etude des Tumeurs à Calcitonine].
    Cohen R; Buchsenschutz B; Estrade P; Gardet P; Modigliani E
    Presse Med; 1996 Nov; 25(37):1819-22. PubMed ID: 8991034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC).
    Cohen R; Campos JM; Salaün C; Heshmati HM; Kraimps JL; Proye C; Sarfati E; Henry JF; Niccoli-Sire P; Modigliani E
    J Clin Endocrinol Metab; 2000 Feb; 85(2):919-22. PubMed ID: 10690910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic variables and calcitonin in medullary thyroid cancer.
    Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
    Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medullary thyroid carcinoma: evolution of concepts].
    Franc B; Modigliani E
    Arch Anat Cytol Pathol; 1998; 46(1-2):100-11. PubMed ID: 9754365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic factors of survival without clinical recurrences in medullary thyroid carcinoma: apropos of 52 operated cases].
    Raffaitin P; Hamy A; Mirallie E; Meurette G; Duplessis R; Lemeunier P; Murat A; Le Bodic M; Le Neel JC; Paineau J; Visset J
    Ann Endocrinol (Paris); 1999 Dec; 60(6):435-42. PubMed ID: 10617796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical analysis of histomorphological findings in medullary thyroid carcinoma: distinction between the different familial forms of the disease. G.E.T.C. Groupe d'Etude des Tumeurs a Calcitonine.
    Franc B; Rosenberg-Bourgin M; Auvert B; Caillou B; Dutrieux-Berger N; Floquet J; Houcke-Lecomte M; Justrabo E; Labat-Moleur F; Le Bodic MF
    Henry Ford Hosp Med J; 1992; 40(3-4):261-3. PubMed ID: 1362419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.
    Valenciaga A; Grubbs EG; Porter K; Wakely PE; Williams MD; Cote GJ; Vasko VV; Saji M; Ringel MD
    Thyroid; 2017 Dec; 27(12):1523-1533. PubMed ID: 29105562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).
    Nocera M; Baudin E; Pellegriti G; Cailleux AF; Mechelany-Corone C; Schlumberger M
    Br J Cancer; 2000 Sep; 83(6):715-8. PubMed ID: 10952773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Histological variants of thyroid medullary carcinoma].
    Raĭkhlin NT; Smirnova EA; Satylganov IZh
    Arkh Patol; 2001; 63(3):10-4. PubMed ID: 11452645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
    Schlumberger M; Abdelmoumene N; Delisle MJ; Couette JE
    Br J Cancer; 1995 Feb; 71(2):363-5. PubMed ID: 7530987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
    Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
    Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
    Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.
    Kebebew E; Ituarte PH; Siperstein AE; Duh QY; Clark OH
    Cancer; 2000 Mar; 88(5):1139-48. PubMed ID: 10699905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients.
    Scopsi L; Sampietro G; Boracchi P; Del Bo R; Gullo M; Placucci M; Pilotti S
    Cancer; 1996 Nov; 78(10):2173-83. PubMed ID: 8918412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal Trends in the Presentation, Treatment, and Outcome of Medullary Thyroid Carcinoma: An Israeli Multicenter Study.
    Hirsch D; Twito O; Levy S; Bachar G; Robenshtok E; Gross DJ; Mazeh H; Benbassat C; Grozinsky-Glasberg S
    Thyroid; 2018 Mar; 28(3):369-376. PubMed ID: 29402183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades.
    Dinneen SF; Valimaki MJ; Bergstralh EJ; Goellner JR; Gorman CA; Hay ID
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2041-5. PubMed ID: 7608252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lymph node involvement and prognosis in medullary cancers of the thyroid gland].
    Mathonnet M; Cubertafond P; Teissier MP; Boutros-Toni F; Gainant A
    Chirurgie; 1994-1995; 120(12):117-22. PubMed ID: 8746014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma.
    Bhattacharyya N
    Otolaryngol Head Neck Surg; 2003 Jan; 128(1):115-23. PubMed ID: 12574769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.